Developing Story
ETHIC Act – Eliminating Thickets to Increase Competition (Pharmaceutical Patent Reform, 2026)
The ETHIC Act, introduced in May 2025 with bipartisan House support, targets pharmaceutical patent thickets that delay generic drug competition, and advocacy groups are pushing for rapid committee markup as of April 2026. If enacted, it would materially affect pharmaceutical patent prosecution strategy and generic market entry timelines. The bill's progress through the House Judiciary Committee is a key near-term indicator.
Importance: 78%Confidence: 82%Mentions: 1Updated: May 4, 2026
## Overview
The "Eliminating Thickets to Increase Competition" (ETHIC) Act was introduced in the U.S. House of Representatives in May 2025 by Representative Jodey Arrington (R-TX), joined by two other Republicans and four Democrats, according to IPWatchdog (April 15, 2026). In April 2026, a coalition of consumer, patient, healthcare provider, and academic groups submitted a letter to the House Judiciary Committee urging rapid markup of the bill (IPWatchdog, April 15, 2026).
## Core Provisions
The bill targets so-called "patent thickets" — clusters of overlapping patents used by pharmaceutical companies to extend exclusivity beyond the life of a primary drug patent. Specific mechanisms reportedly addressed include:
- Restrictions on the filing of continuation patents that effectively delay generic competition
- Enhanced USPTO scrutiny of secondary pharmaceutical patents
- Potentially accelerated inter partes review pathways for pharmaceutical patent challenges
The precise text and full provisions had not been publicly detailed in available reporting as of this entry.
## Coalition Support
The April 2026 letter to the House Judiciary Committee was signed by groups self-described as representing consumers, patients, health care providers, and academic experts in pharmaceutical policy and patent law (IPWatchdog, April 15, 2026). The bipartisan sponsorship structure suggests the bill is positioned to avoid strict partisan framing.
## Strategic Significance
- **Generic and biosimilar entry**: If enacted, the bill could materially accelerate generic drug market entry, affecting branded pharmaceutical valuations.
- **Patent prosecution strategy**: Pharmaceutical companies may need to reassess continuation filing strategies and secondary patent portfolios.
- **PTAB interaction**: Legislation may overlap with or reinforce existing PTAB institution rate trends (see: IPR Institution Rate Decline – PTAB 2024–2026).
- **Investor relevance**: Biotech and pharmaceutical portfolio valuations often rest partly on exclusivity runway; thicket restrictions compress that runway.
## Legislative Status
As of April 2026, the bill had not yet received a committee markup. Advocacy groups were actively pushing the House Judiciary Committee to schedule one (IPWatchdog, April 15, 2026).
## Anticipated Developments
Committee markup scheduling, pharmaceutical industry lobbying response, and CBO scoring are the near-term milestones to track. Senate companion legislation has not been reported.